2,096
Views
6
CrossRef citations to date
0
Altmetric
RESEARCH ARTICLE

Pharmacokinetics and efficacy of a ketorolac-loaded ocular coil in New Zealand white rabbits

ORCID Icon, , , , , & show all
Pages 400-407 | Received 17 Nov 2020, Accepted 26 Jan 2021, Published online: 17 Feb 2021

References

  • Bertens CJF, Gijs M, van den Biggelaar F, Nuijts R. (2018). Topical drug delivery devices: a review. Exp Eye Res 168:149–60.
  • Bertens CJF, Martino C, van Osch MC, et al. (2020). Design of the ocular coil, a new device for non-invasive drug delivery. Eur J Pharm Biopharm 150:120–30.
  • Bertens CJF, Zhang S, Erckens RJ, et al. (2019). Confocal Raman spectroscopy: evaluation of a non-invasive technique for the detection of topically applied ketorolac tromethamine in vitro and in vivo. Int J Pharm 570:118641.
  • Bucci FA Jr, Waterbury LD. (2009). Aqueous prostaglandin E(2) of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing. Adv Therapy 26:645–50.
  • Bucci FA Jr, Waterbury LD. (2011). A randomized comparison of to-aqueous penetration of ketorolac 0.45%, bromfenac 0.09% and nepafenac 0.1% in cataract patients undergoing phacoemulsification. Curr Med Res Opin 27:2235–9.
  • Eaton AM, Gordon GM, Konowal A, et al. (2015). A novel eye drop application monitor to assess patient compliance with a prescribed regimen: a pilot study. Eye (Lond) 29:1383–91.
  • Farkouh A, Frigo P, Czejka M. (2016). Systemic side effects of eye drops: a pharmacokinetic perspective. Clin Ophthalmol 10:2433–41.
  • Gaudana R, Ananthula HK, Parenky A, Mitra AK. (2010). Ocular drug delivery. Aaps J 12:348–60.
  • Graff G, Brady MT, Gamache DA, et al. (1998). Transient loss of prostaglandin synthetic capacity in rabbit iris-ciliary body following anterior chamber paracentesis. Ocul Immunol Inflamm 6:227–38.
  • Hughes PM, Olejnik O, Chang-Lin JE, Wilson CG. (2005). Topical and systemic drug delivery to the posterior segments. Adv Drug Deliv Rev 57:2010–32.
  • Lee SB, Geroski DH, Prausnitz MR, Edelhauser HF. (2004). Drug delivery through the sclera: effects of thickness, hydration, and sustained release systems. Exp Eye Res 78:599–607.
  • Mohindroo C, Ichhpujani P, Kumar S. (2015). How 'Drug Aware' are our *Glaucoma patients? J Curr Glaucoma Pract 9:33–7.
  • Motulsky HJ, Brown RE. (2006). Detecting outliers when fitting data with nonlinear regression – a new method based on robust nonlinear regression and the false discovery rate. BMC Bioinformatics 7:123.
  • Olthoff CM, Hoevenaars JG, van den Borne BW, et al. (2009). Prevalence and determinants of non-adherence to topical hypotensive treatment in Dutch glaucoma patients. Graefes Arch Clin Exp Ophthalmol 247:235–43.
  • Pijls RT, Cruysberg LP, Nuijts RM, et al. (2007). Capacity and tolerance of a new device for ocular drug delivery. Int J Pharm 341:152–61.
  • Pijls RT, Hanssen HH, Nuijts RM, et al. (2006). In vivo tolerance and kinetics of a novel ocular drug delivery device. J Control Release 116:e47-49–e49.,
  • Pijls RT, Hanssen HH, Nuijts RM, Koole LH. (2004). Flexible coils with a drug-releasing hydrophilic coating: a new platform for controlled delivery of drugs to the eye? Biomed Mater Eng 14:383–93.
  • Pijls RT, Sonderkamp T, Daube GW, et al. (2005). Studies on a new device for drug delivery to the eye. Eur J Pharm Biopharm 59:283–8.
  • Sharma NS, Acharya SK, Nair AP, et al. (2019). Dopamine levels in human tear fluid. Indian J Ophthalmol 67:38–41.
  • Unger WG, Cole DF, Hammond B. (1975). Disruption of the blood–aqueous barrier following paracentesis in the rabbit. Exp Eye Res 20:255–70.
  • Urtti A, Salminen L. (1993). Minimizing systemic absorption of topically administered ophthalmic drugs. Surv Ophthalmol 37:435–56.
  • Urtti A. (2006). Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 58:1131–5.
  • US Pharmacopeia 2018 USP Ketorolac tromethamine. [cited 2018 November 26]; Available from: http://www.pharmacopeia.cn/v29240/usp29nf24s0_m44006.html
  • Visco DM, Bedi R. (2020). Effect of intracameral phenylephrine 1.0%-ketorolac 0.3% on postoperative cystoid macular edema, iritis, pain, and photophobia after cataract surgery. J Cataract Refract Surg 46:867–72.
  • Walters T, Raizman M, Ernest P, et al. (2007). In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg 33:1539–45.